ArticleOpen access Macedonian journal of medical sciences2018
Myasthenia Gravis and Associated Diseases.
Article in Open access Macedonian journal of medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Dyslipidemia in Myasthenia Gravis: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Diabetes mellitus in patients with myasthenia gravis: a systematic review and meta-analysis.Endocrine · 2025Pooled it
- Single-cell RNA-sequencing of myasthenia gravis reveals transcriptional heterogeneity and dysfunction of immune cell populations.International immunology · 2026Article
- Evaluation of nonmotor symptoms in myasthenia gravis patients.Turkish journal of medical sciences · 2025Article
- The Association Between Myasthenia Gravis and Higher Extrathymic Cancer Risk.Brain and behavior · 2025Article
- Association of Myasthenia Gravis With Autoimmune Thyroid Disease: A Bidirectional Mendelian Randomization Study.Brain and behavior · 2025Article
- Methylprednisolone pulse versus docetaxel in recurrent thymoma with myasthenia gravis.Frontiers in neurology · 2025Article
- Efgartigimod for patients with thymoma associated generalized myasthenia gravis during the perioperative period: a four-case report.Frontiers in immunology · 2025Article
- Defective autophagy and autophagy activators in myasthenia gravis: a rare entity and unusual scenario.Autophagy · 2024Review
- Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.CNS drugs · 2024Review
- Systemic Inflammatory Response Index, a Potential Inflammatory Biomarker in Disease Severity of Myasthenia Gravis: A Pilot Retrospective Study.Journal of inflammation research · 2024Article
- Unveiling the uncommon: a captivating case of multiple autoimmune syndrome.Archive of clinical cases · 2024Article
- Genetic, serological and clinical evaluation of childhood myasthenia syndromes- single center subgroup analysis experience in Turkey.Acta neurologica Belgica · 2023Article
- Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report.Experimental and therapeutic medicine · 2023Article
- Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows.Brain sciences · 2023Review
- Review
- Simultaneous Myasthenic Crisis With Thyrotoxic Crisis in an Adult Male: An Autoimmune Overlap.Cureus · 2023Article
- Evaluation of the quality of patient involvement in a patient-led analysis of the lived experience of a rare disease.Research involvement and engagement · 2023Article
- Observational
- The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis.Neurology and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyasthenia gravis (MG) is an autoimmune disease caused by the action of specific antibodies to the postsynaptic membrane of the neuromuscular junction, leading to impaired neuromuscular transmission. Patients with MG have an increased incidence of other autoimmune diseases.
aimto determine the presence of other associated diseases in patients with MG.
methodA group of 127 patients with MG followed in 10 years period, in which the presence of other associated diseases has been analysed.
resultsThe sex ratio is in favour of the female sex, the average age of the initial manifestation of the disease is less than 50 years, 65.4% of the patients with MG have another disease. 15.0% patients have associated another autoimmune disease. Thyroid disease is the most common associated with MG, rarely rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and other autoimmune diseases. Other diseases include hypertension, heart disease, diabetes, respiratory diseases, dyslipidemia. 10.2% of the patients are diagnosed with extrathymic tumours of various origins.
conclusionAssociated diseases are common in patients with MG, drawing attention to the possible common basis for their coexistence, as well as their impact on the intensity and treatment of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.